BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26317545)

  • 1. Upregulation of COL6A1 is predictive of poor prognosis in clear cell renal cell carcinoma patients.
    Wan F; Wang H; Shen Y; Zhang H; Shi G; Zhu Y; Dai B; Ye D
    Oncotarget; 2015 Sep; 6(29):27378-87. PubMed ID: 26317545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ITGA2B and ITGA8 are predictive of prognosis in clear cell renal cell carcinoma patients.
    Lu X; Wan F; Zhang H; Shi G; Ye D
    Tumour Biol; 2016 Jan; 37(1):253-62. PubMed ID: 26198048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma.
    Zhou J; Deng Z; Chen Y; Gao Y; Wu D; Zhu G; Li L; Song W; Wang X; Wu K; He D
    Urol Oncol; 2015 Mar; 33(3):113.e9-17. PubMed ID: 25192834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased expression of CTR2 predicts poor prognosis of patients with clear cell renal cell carcinoma.
    Xia Y; Liu L; Long Q; Bai Q; Wang J; Xu J; Guo J
    Urol Oncol; 2016 Jan; 34(1):5.e1-9. PubMed ID: 26411550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.
    Xu WH; Shi SN; Xu Y; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
    J Transl Med; 2019 Nov; 17(1):363. PubMed ID: 31703694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma.
    Xu WH; Shi SN; Wang J; Xu Y; Tian X; Wan FN; Cao DL; Qu YY; Zhang HL; Ye DW
    Med Sci Monit; 2019 Dec; 25():9458-9470. PubMed ID: 31825950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Neural Wiskott-Aldrich Syndrome Protein in Clear Cell Renal Cell Carcinoma and Its Correlation with Clinicopathological Features.
    Liu GH; Chen J; Ji ZG; Zhou L
    Urol Int; 2015; 95(1):79-85. PubMed ID: 25115631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of long non-coding RNA SPRY4-IT1 predicts poor prognosis of clear cell renal cell carcinoma.
    Zhang HM; Yang FQ; Yan Y; Che JP; Zheng JH
    Int J Clin Exp Pathol; 2014; 7(9):5801-9. PubMed ID: 25337221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma.
    Pan D; Xu L; Liu H; Zhang W; Liu W; Liu Y; Fu Q; Xu J
    Cancer Sci; 2015 May; 106(5):592-7. PubMed ID: 25702890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ΑB-crystallin in clear cell renal cell carcinoma: tumor progression and prognostic significance.
    Ho PY; Chueh SC; Chiou SH; Wang SM; Lin WC; Lee IL; Yang HY; Peng HC; Lai MK
    Urol Oncol; 2013 Oct; 31(7):1367-77. PubMed ID: 22417627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of P53-induced Ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma.
    Wu XR; Sha JJ; Liu DM; Chen YH; Yang GL; Zhang J; Chen YY; Bo JJ; Huang YR
    Eur J Surg Oncol; 2013 Jan; 39(1):100-6. PubMed ID: 23102595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High CLEC-2 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma.
    Xiong Y; Liu L; Xia Y; Wang J; Xi W; Bai Q; Qu Y; Long Q; Xu J; Guo J
    Oncotarget; 2016 Sep; 7(39):63661-63668. PubMed ID: 27564117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin-8 predicts postoperative recurrence of patients with localized T1 clear cell renal cell carcinoma.
    Liu Y; Xu L; Zhu Y; Zhang W; Liu W; Liu H; Xu J
    Urol Oncol; 2015 Mar; 33(3):112.e1-8. PubMed ID: 25499921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma.
    Minardi D; Santoni M; Lucarini G; Mazzucchelli R; Burattini L; Conti A; Bianconi M; Scartozzi M; Milanese G; Primio RD; Montironi R; Cascinu S; Muzzonigro G
    Urol Oncol; 2015 Mar; 33(3):113.e1-7. PubMed ID: 25069421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
    Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
    J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of MUC3A is associated with poor prognosis in localized clear-cell renal cell carcinoma.
    Niu T; Liu Y; Zhang Y; Fu Q; Liu Z; Wang Z; Fu H; Xu J; Liu K
    Oncotarget; 2016 Aug; 7(31):50017-50026. PubMed ID: 27374181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
    Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
    Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of CXC chemokine receptor 6 associates with poor prognosis in patients with clear cell renal cell carcinoma.
    Chang Y; Zhou L; Xu L; Fu Q; Yang Y; Lin Z; Xu J
    Urol Oncol; 2017 Dec; 35(12):675.e17-675.e24. PubMed ID: 28918166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma.
    Glaser ZA; Love HD; Guo S; Gellert L; Chang SS; Herrell SD; Barocas DA; Penson DF; Cookson MS; Clark PE
    Urol Oncol; 2017 May; 35(5):286-293. PubMed ID: 28108243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma.
    Kruck S; Merseburger AS; Hennenlotter J; Scharpf M; Eyrich C; Amend B; Sievert KD; Stenzl A; Bedke J
    BJU Int; 2012 May; 109(10):1565-70. PubMed ID: 21981759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.